Joel Savage en Lifestyle, Communications and journalism, Healthcare Freelance Journalist, writer and author • A MIXTURE OF PERIODICALS 25/11/2016 · 2 min de lectura · +200

THE DEADLY AND SYMPTOM-LESS THREAT OF EBOLA

THE DEADLY AND SYMPTOM-LESS THREAT OF EBOLA

Ebola mutation is still a threat if a patient is declared Ebola free

After Ebola patients declared free of Ebola in the blood, many probably developed a symptom less Ebola Mutation in the central nervous system and separated genetic reproduction center. This Symptom less  Ebola can relapse into contagious Ebola at any time, implicating that potentially ten thousand ticking time bombs walk around in the Mano River Region.

Also it is not impossible that this new form of Ebola could  be contagious without exterior body fluids or even become aerosol in further mutations. If that happens the prediction from W.H.O. and CDC in 2014, that millions of people will die of Ebola in the Mano River  Region will become a self-prophesying reality.  WHY THESE MEDICINES WORK?  Atorvastatin and Irbesartan can treat the dysfunction of the endothelial cells that line the blood vessels, preventing the leakage of fluid from the blood into tissues.

This maintains blood volume, and cuts down  on fluid loss from diarrhea. By maintaining fluid balance, treatment allows patients to live long enough to develop their own immune response to EBOV and other diseases, and they use that response to get rid of  the virus. SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs) Before the Ebola virus enters the cytoplasm in the blood it can be blocked with a specific Selective  Estrogen Receptor Modulator drug (SERM) even before it enters the cell.

According to the US Army  Medical Research Institute of Infectious Diseases, and the University of Virginia, SERM inhibits multiplication of the ebola virus within the cell lessening the burden of infection. 
On 19 June 2013, the FDA approved their application to inhibit Ebola Virus Infection through cell based mechanisms unrelated to the classical estrogen signaling pathing with Selective Estrogen Receptor Modulators specifically the  antiviral activity against the type species Zaire Ebolavirus (EBOV).

The inhabitation occurs after viral  binding and internalization. STATINS .When the Ebola virus already entered a cell, STATINS can block the transport of viruses to cytoplasm of cell volume so they cannot multiply and prevents vascular leakage. One specific substance the Ebola virus requires to move around is the cholesterol transporter Niemann-Pick C1. Researchers discovered that patients without Nieman-Pick C1 (NPC1) survived Ebola because there was no means to transport the virus any longer. susceptibility.

Apoptosis of lymphocytes It is justifiable to conclude that extrapolating NPC1 with STATINS blocks the action of NPC1 and has the possibility of thwarting the Ebola infection  while enabling the body to recover.  ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) The Angiotensin enzyme is a devastating blood vessel narrower (vasoconstrictor) while reducing vasodilator (widening) responses in arteries. 

Like with severe sepsis, Angiotensin causes intestinal  bleeding caused by an overreaction of the immune system, resulting in organ failure which is a complication that in most cases kills Ebola patients. Angiotensin Receptor Blockers (ARB) interrupt the  renin-angiotensin hormone system’s over-activity by blocking a specific receptor that mediates the pathogenic (inflammatory) activity of Angiotensin which deregulates blood pressure and water fluid  balance leading to hypertension, heart failure, and kidney & liver failure.

It reduces the amount of harmful cytokine release. ARBs modify or reverse abnormalities in blood vessel walls’ function and blood coagulation in patients with sepsis and Ebola, reducing the incidence of organ failure which is one of the complications that often kills Ebola patients.    

W.H.O.’s CONTRADICTION  

According to a meeting of international ethics experts convened by WHO on the 8 August 2014, if experimental drugs – i.e. those that have not been tested and licensed for use in humans to help them fight  Ebola infection – are given to patients in the outbreak, “there is a moral obligation to collect and share all data generated.”  
“Unfortunately this is not always taking place. Several interventions, including amiodarone, statins, antihypertensives and even intravenous ozone, have been tried by various medical teams,” Friede says.  

“Even where some data have been collected, they have not always been sufficient for a full assessment of the safety and efficacy of these approaches by WHO.”  “Reports on these ad-hoc tests, which have not gone through formal approval processes, have led to debate in social media about whether Africans were being used as human guinea pigs,” he says. There are also other concerns. All trials of Ebola therapeutics must be conducted under rigorous biosafety  conditions, which means using full protective gear.

Read more: https://secretsofaidsandebola.blogspot.be/2016/11/the-deadly-and-symptom-less-threat-of.html